<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="37714">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02615561</url>
  </required_header>
  <id_info>
    <org_study_id>17534</org_study_id>
    <nct_id>NCT02615561</nct_id>
  </id_info>
  <brief_title>Curing Atopic Dermatits in Children With a Commerical Medical Device and Maintaining Healthy Skin by Using a New Cosmetic Product</brief_title>
  <official_title>Multicenter, Two-phase Exploratory Clinical Trial to Examine Efficacy and Safety After Open-label Topical Administration of a Medical Device (Bepanthen Itch Relief Cream) for Treatment of Acute Flare-ups Followed by Topical Administration of a New Cosmetic Bepanthen Product or a Cosmetic Comparator in a Parallel-group, Randomized, Investigator-blinded Care Phase for Skin Care in the Remission Phase in Infants With Mild Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Curing mild atopic dermatis in children with a commerical medical device (Bepanthen
           Itch Relief Cream).

        2. Maintaining healthy skin by using a new cosmetic Bepanthen product or a commercially
           available cosmetic product
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy: Time to flare up of new AD symptoms assessed by SCORAD (SCORing AD) index for evaluation of disease improvement after and during treatment</measure>
    <time_frame>up to 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy: Time to flare up of new AD symptoms assessed by Local SCORAD score for Intensity on a representative lesion</measure>
    <time_frame>up to 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy: Time to flare up of new AD symptoms assessed by Dryness assessed at single representative lesion</measure>
    <time_frame>up to 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy: Time to flare up of new AD symptoms assessed by Pruritus assessment in subjects diary</measure>
    <time_frame>up to 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy: Time to flare up of new AD symptoms assessed by Sleeplessness assessment in subjects diary</measure>
    <time_frame>up to 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy: Time to flare up of new AD symptoms assessed by Quality of life questionnaire</measure>
    <time_frame>up to 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety: Number of adverse events (AE)</measure>
    <time_frame>up to 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: physical examination</measure>
    <time_frame>up to 3 months</time_frame>
    <description>Weight and height</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety: vital signs</measure>
    <time_frame>up to 3 months</time_frame>
    <description>Systolic and diastolic blood pressure, Heart rate</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">136</enrollment>
  <condition>Dermatitis, Atopic</condition>
  <arm_group>
    <arm_group_label>Phase 1 (Cure phase)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Efficacy and safety of the medical device Bepanthen Itch Relief Cream in children´s mild AD (responders will enter study phase 2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 (Care phase) / Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Efficacy and safety of the new cosmetic Bepanthen test product in maintaining healthy skin in the remission phase after cure of children´s mild AD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 (Care phase) / Arm 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Efficacy and safety of Stelatopia (cosmetic comparator) in maintaining healthy skin in the remission phase after cure of children´s mild AD</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bepanthen Itch Relief Cream: Phoenix 2 (Bepanthen Sensiderm, BAY207543)</intervention_name>
    <description>2-3 times daily using multiples of Finger Tip Units (FTUs) depending on size of the area of the flares</description>
    <arm_group_label>Phase 1 (Cure phase)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>New cosmetic Bepanthen product: Pumpkin (BAY207543)</intervention_name>
    <description>Twice daily on the whole body; about 10 FTUs (i.e. 5g) per application depending on age of subject</description>
    <arm_group_label>Phase 2 (Care phase) / Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Stelatopia (cosmetic comparator)</intervention_name>
    <description>Twice daily on the whole body; about 10 FTUs (i.e. 5g) per application depending on age of subject</description>
    <arm_group_label>Phase 2 (Care phase) / Arm 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written parents' informed consent to have their child participate in the study and
             attend the study procedures and processes as outlined in the protocol

          -  Male or female babies/children aged between 1 month and 4 years

          -  Mild AD presenting a maximum SCORAD of 25 (at Screening and Baseline)

          -  Acute flare-up phase

          -  Local SCORAD ≥ 5 on the target area (at Screening and Baseline)

          -  Skin type I - IV according to Fitzpatrick

        Exclusion Criteria:

          -  Any other skin disease at the target area that would interfere the clinical
             assessment in the opinion of the investigator

          -  Known allergies to any of the ingredients of the IMPs

          -  Any other adjuvant therapy for AD (UV therapy, probiotics, homeopathy etc.) within 30
             days before Baseline as well as during the entire study

          -  Any use of another topical emollient or other established treatment for AD during
             Phase 1 (cure phase) and Phase 2 (care phase) at the site of flares (AD lesions).
             Exception are usual hygienic products in the nappy area
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Month</minimum_age>
    <maximum_age>4 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Karlsruhe</city>
        <state>Baden-Württemberg</state>
        <zip>76189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kehl</city>
        <state>Baden-Württemberg</state>
        <zip>77694</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Schwäbisch Hall</city>
        <state>Baden-Württemberg</state>
        <zip>74523</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Welzheim</city>
        <state>Baden-Württemberg</state>
        <zip>73642</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Altdorf b. Nürnberg</city>
        <state>Bayern</state>
        <zip>90518</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Neustadt / Aisch</city>
        <state>Bayern</state>
        <zip>91413</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rosenheim</city>
        <state>Bayern</state>
        <zip>83026</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bramsche</city>
        <state>Niedersachsen</state>
        <zip>49565</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bochum</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Datteln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>45711</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dortmund</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44143</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Frankenthal</city>
        <state>Rheinland-Pfalz</state>
        <zip>67227</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Neumünster</city>
        <state>Schleswig-Holstein</state>
        <zip>24534</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Erfurt</city>
        <state>Thüringen</state>
        <zip>99086</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 16, 2016</lastchanged_date>
  <firstreceived_date>October 23, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Efficacy</keyword>
  <keyword>Atopic dermatitis</keyword>
  <keyword>Cosmetic products</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diphenhydramine</mesh_term>
    <mesh_term>Promethazine</mesh_term>
    <mesh_term>Pantothenic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
